Cargando…

Does Proton Pump Inhibitor Increase the Clostridium difficile Infection Risk in the Treatment and Prophylaxis of Stress Ulcers than Histanime-2 Receptor Antagonist?

Detalles Bibliográficos
Autor principal:	Eun, Chang Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669586/ https://www.ncbi.nlm.nih.gov/pubmed/29081208 http://dx.doi.org/10.5009/gnl17430

Ejemplares similares

Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients
por: Ro, Youngouk, et al.
Publicado: (2016)

Proton pump inhibitors and the incidence of Clostridium difficile on the intensive care unit
por: Whitehead, I, et al.
Publicado: (2007)

The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection
por: Tawam, Dania, et al.
Publicado: (2021)

Comparison of the Hospital-Acquired Clostridium difficile Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis
por: Azab, Mohamed, et al.
Publicado: (2017)

Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection
por: Inghammar, Malin, et al.
Publicado: (2021)

Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
por: Weiss, Karl, et al.
Publicado: (2015)

Comparison of proton pump inhibitors and histamine 2 receptor antagonists for stress ulcer prophylaxis in the intensive care unit
por: Song, Myung Jin, et al.
Publicado: (2021)

Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment
por: Bradley, Evan Stuart, et al.
Publicado: (2019)

515. Estimating the Effect of Proton Pump Inhibitor Stewardship in Reducing Clostridium difficile Transmission
por: Lofgren, Eric, et al.
Publicado: (2018)

Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients
por: Barletta, Jeffrey F, et al.
Publicado: (2014)

Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients
por: Pohl, John F., et al.
Publicado: (2011)

Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis
por: Trifan, Anca, et al.
Publicado: (2017)

Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy
por: Dos Santos-Schaller, Ophélie, et al.
Publicado: (2016)

Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility
por: Seto, Charlie T, et al.
Publicado: (2014)

Proton Pump Inhibitors and Clostridium Difficile Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem?
por: Patil, Rashmee, et al.
Publicado: (2013)

Proton Pump Inhibitor Prophylaxis After Gastric Bypass Does Not Cause Hypomagnesemia
por: Boerlage, Thomas C. C., et al.
Publicado: (2016)

Erratum to: Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility
por: Seto, Charlie T., et al.
Publicado: (2016)

Proton Pump Inhibitors Should be Used with Caution in Critically Ill Patients to Prevent the Risk of Clostridium difficile Infection
por: Min, Jung Hwa, et al.
Publicado: (2016)

Effects of proton pump inhibitor versus H2-receptor antagonist stress ulcer prophylaxis on ventilator-associated pneumonia: a pilot study
por: Fogas, JF, et al.
Publicado: (2013)

Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-Analysis
por: Tleyjeh, Imad M., et al.
Publicado: (2012)

The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model
por: Tomkovich, Sarah, et al.
Publicado: (2019)

Proton pump inhibitors versus histamine-2 receptor antagonists for stress ulcer prophylaxis during extracorporeal membrane oxygenation: a propensity score-matched analysis
por: Kondo, Yutaka, et al.
Publicado: (2020)

H(2) antagonists, proton pump inhibitors and COVID-19
por: Hirota, Kazuyoshi
Publicado: (2022)

Stress ulcer prophylaxis with proton pump inhibitors or histamine 2 receptor antagonists in critically ill adults - a meta-analysis of randomized controlled trials with trial sequential analysis
por: Zhou, Xiaoyang, et al.
Publicado: (2019)

Proton Pump Inhibitors: More Indigestion than Relief?
por: Malavade, P., et al.
Publicado: (2017)

Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?
por: Taştemur, Şeyma, et al.
Publicado: (2020)

802. Proton Pump Inhibitors Increase Clostridioides difficile Disease Severity Controlling for Infecting Strains
por: Fallatah, Saad, et al.
Publicado: (2020)

Reducing Inappropriate Proton Pump Inhibitors Use for Stress Ulcer Prophylaxis in Hospitalized Patients: Systematic Review of De-Implementation Studies
por: Orelio, Claudia C., et al.
Publicado: (2021)

A Review of the Safety and Efficacy of Vaccines as Prophylaxis for Clostridium difficile Infections
por: Henderson, Mackenzie, et al.
Publicado: (2017)

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

P029: Regional differences in Clostridium difficile infections (CDI) in relation to fluoroquinolone (FQ) and proton pump inhibitor (PPI) use, Finland, 2008-2011
por: Kanerva, M, et al.
Publicado: (2013)

In vitro and in vivo antagonistic activity of new probiotic culture against Clostridium difficile and Clostridium perfringens
por: Golić, Nataša, et al.
Publicado: (2017)

Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection
por: Lin, Cheng-Yu, et al.
Publicado: (2022)

Antibiotic-Associated Diarrhea: Candidate Organisms other than Clostridium Difficile
por: Song, Hyun Joo, et al.
Publicado: (2008)

2389. Assessing the Time Course of Proton Pump Inhibitor Use and Clostridioides difficile Infection
por: Panagos, Katherine, et al.
Publicado: (2019)

Proton pump inhibitors versus histamine-2 receptor blockers for stress ulcer prophylaxis in patients with sepsis: a retrospective cohort study
por: Huang, Minqiang, et al.
Publicado: (2021)

Clostridium difficile-associated diarrhea following the therapy with antibiotic and proton pump inhibitors in a 77-year-old man with several comorbidities: A case report
por: Lv, Xiaoqun, et al.
Publicado: (2019)

Effects of Proton Pump Inhibitors and H(2) Receptor Antagonists on the Ileum Motility
por: Kurt, Atilla, et al.
Publicado: (2011)

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
por: Loftus, Edward V, et al.
Publicado: (2022)

496. Secondary Prophylaxis for Clostridium difficile Infection: A Physician Practice Assessment
por: Sampson, Mindy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_34edjum6bs0buus26kt748cila